

Topical Collection

Prostate Cancer—from Molecular Mechanisms to Clinical Care

Message from the Collection Editors

Prostate cancer is the second leading cause of cancer-related death in men worldwide. The treatment options for men with advanced form of the disease have been focused on targeting the androgen receptor signaling axes for decades. Recent technical developments that allow better resolution have increased our understanding of the molecular mechanisms that are important for prostate cancer biology and disease evolution. As new, possibly druggable, targets are discovered and novel treatment options enter clinical trials, the need to improve the link between molecular discoveries and clinical management also increases. This Collection will focus on the current status and challenges in treating early and progressive prostate cancer, covering topics from basic research and technical developments to specific new and emerging targets, and the clinical management of prostate cancer patients.

Collection Editors

Dr. Alfonso Urbanucci

Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway

Dr. Delila Gasi Tandefelt

Sahlgrenska Cancer Center, Institute of clinical studies, University of Gothenburg, Gothenburg, Sweden



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/47523

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)